JMP Securities analyst Patrick Walravens maintains C3.ai (NYSE:AI) with a Market Outperform and lowers the price target from $25 to $19.
Organovo Highlights FXR314 Combination Therapy Potential And Plan
Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in
